Streetbeat News

Earnings

VRTX

Vertex Pharmaceuticals provided its FY24 financial guidance, projecting product revenues of $10.55B-$10.75B, driven by growth in CF treatments and the launch of CASGEVY. Expenses are expected to be $4.3B-$4.4B. Key highlights include the expansion of CF patient base and approvals for KAFTRIO in the EU and UK for younger patients, and a pending approval for additional CF mutations in the EU and other regions.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:08 pm

CHGG

Chegg (NYSE:CHGG) reported Q4 2023 earnings of $0.36 per share, meeting analyst consensus. Quarterly sales were $188.00 million, slightly above the consensus of $187.35 million but marked an 8.38% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:08 pm

KE

Kimball Electronics (NASDAQ:KE) reported Q2 adjusted EPS of $0.33, missing the $0.44 estimate, and sales of $421.24M, missing the $435.67M estimate. This represents a 25% decrease in EPS and a 3.54% decrease in sales from the same period last year.

Portfolio Pulse from totan@benzinga.com

February 05, 2024 | 9:07 pm

CHGG

Chegg (NYSE:CHGG) reported Q4 sales of $188.00M, missing the consensus estimate of $187.35M by 100.00%. This represents a 100.00% decrease from the $205.19M sales reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:07 pm

VRTX

Vertex Pharmaceuticals (NASDAQ:VRTX) exceeded Q4 earnings and sales estimates with an EPS of $4.20, surpassing the $4.10 forecast, and reported sales of $2.52B, slightly above the $2.51B estimate. This represents an 11.7% increase in EPS and a 9.32% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:07 pm

SPG

Simon Property Group (SPG) reported Q4 earnings of $3.69 per share, surpassing the consensus estimate of $3.34 by 10.48%. Quarterly sales reached $1.53 billion, exceeding the $1.36 billion estimate by 12.38%, marking a 9.07% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:06 pm

PLTR

Palantir Technologies (PLTR) reported Q4 2023 earnings of $0.08 per share, meeting analyst estimates, with sales of $608M surpassing the $602.41M forecast. This represents a 19.54% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:06 pm

VRNS

Varonis Systems (NASDAQ:VRNS) reported Q4 adjusted earnings of $0.27 per share, surpassing the consensus estimate of $0.23 by 17.39%. Year-over-year, this represents a 28.57% increase from $0.21 per share. Quarterly sales reached $154.10 million, exceeding estimates of $151.83 million by 1.49% and marking an 8.05% increase from $142.62 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:06 pm

GBDC

Golub Capital BDC (NASDAQ:GBDC) reported Q1 earnings of $0.45 per share, missing the consensus estimate of $0.48 by 6.25%. This represents a 21.62% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:06 pm

SPG

Simon Property Group (SPG) reported Q4 2023 earnings of $3.69 per share, surpassing the analyst consensus estimate of $3.34 by 10.48%.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:06 pm